AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental ...

Alison Dziarmaga, Vice President and U.S. Breast Cancer Franchise Head at AstraZeneca, ...

AstraZeneca (LSE:AZN) is advancing its oral GLP-1 candidate elecoglipron into Phase 3 trials after positive Phase 2b results.

The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...

AstraZeneca said on Monday that patients lost 10.5% of their body weight after 26 weeks in a mid-stage trial of ​its ...

AstraZeneca’s experimental GLP-1 pill cut body weight by nearly 12% in obese patients over 36 weeks and reduced A1C, a metric ...

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout ...

The Lung Cancer Research Foundation (LCRF), in collaboration with AstraZeneca, today announced that two research awards ...

A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss ...

AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...

The approval relies on positive data from the POTOMAC Phase III trial.

View AstraZeneca PLC AZN stock quote prices, financial information, real-time forecasts, and company news from CNN.